Integrative Pan-Cancer Analysis Reveals the Oncogenic Role of MND1 and Validation of MND1’s Role in Breast Cancer

References

• Kang H-A, Shin H-C, Kalantzi A-S, et al. Crystal structure of Hop2-Mnd1 and mechanistic insights into its role in meiotic recombination. Nucleic Acids Res. 2015;43(7):3841–3856. doi:10.1093/nar/gkv172
   Google Scholar
• Zhang Q, Shi R, Bai Y, et al. Meiotic nuclear divisions 1 (MND1) fuels cell cycle progression by activating a KLF6/E2F1 positive feedback loop in lung adenocarcinoma. Cancer Commun. 2021;41(6):492–510. doi:10.1002/cac2.12155
   Google Scholar
• Zelceski A, Francica P, Lingg L, et al. MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells. Cell Rep. 2023;42(5):112484. doi:10.1016/j.celrep.2023.112484
   Google Scholar
• Tsubouchi H, Roeder GS. The Mnd1 protein forms a complex with hop2 to promote homologous chromosome pairing and meiotic double-strand break repair. Mol Cell Biol. 2002;22(9):3078–3088. doi:10.1128/MCB.22.9.3078-3088.2002
   PubMedGoogle Scholar
• Lee W, Iwasaki H, Tsubouchi H, Li H-W. Hop2-Mnd1 and Swi5-Sfr1 stimulate Dmc1 filament assembly using distinct mechanisms. Nucleic Acids Res. 2023;51(16):8550–8562. doi:10.1093/nar/gkad561
   Google Scholar
• Bugreev DV, Huang F, Mazina OM, et al. HOP2-MND1 modulates RAD51 binding to nucleotides and DNA. Nat Commun. 2014;5(1):4198. doi:10.1038/ncomms5198
   Google Scholar
• Tsubouchi H. The Hop2-Mnd1 complex and its regulation of homologous recombination. Biomolecules. 2023;13(4):662. doi:10.3390/biom13040662
   Google Scholar
• Chi P, San Filippo J, Sehorn MG, Petukhova GV, Sung P. Bipartite stimulatory action of the Hop2-Mnd1 complex on the Rad51 recombinase. Genes Dev. 2007;21(14):1747–1757. doi:10.1101/gad.1563007
   Google Scholar
• Wei J, Meng G, Wu J, Zhang Q, Zhang J. Genetic network and gene set enrichment analyses identify MND1 as potential diagnostic and therapeutic target gene for lung adenocarcinoma. Sci Rep. 2021;11(1):9430. doi:10.1038/s41598-021-88948-4
   Google Scholar
• Pezza RJ, Voloshin ON, Vanevski F, Camerini-Otero RD. Hop2/Mnd1 acts on two critical steps in Dmc1-promoted homologous pairing. Genes Dev. 2007;21(14):1758–1766. doi:10.1101/gad.1562907
   Google Scholar
• Fang J, Zhen J, Gong Y, et al. MND1 functions as a potential prognostic biomarker associated with cell cycle and immune infiltration in kidney renal clear cell carcinoma. Aging. 2022;14(18):7416–7442. doi:10.18632/aging.204280
   Google Scholar
• McFarlane RJ, Wakeman JA. Meiosis-like Functions in Oncogenesis: a New View of Cancer. Cancer Res. 2017;77(21):5712–5716. doi:10.1158/0008-5472.CAN-17-1535
   Google Scholar
• Bao Z, Cheng J, Zhu J, et al. Using weighted gene co-expression network analysis to identify increased MND1 expression as a predictor of poor breast cancer survival. Int J Gen Med. 2022;15:4959–4974. doi:10.2147/IJGM.S354826
   PubMed Web of Science ®Google Scholar
• Zhang L, Li X, Zhang J, Xu G. Prognostic implication and oncogenic role of PNPO in Pan-Cancer. Front Cell Dev Biol. 2021;9:763674. doi:10.3389/fcell.2021.763674
   Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The Immune Landscape of Cancer. Immunity. 2018;48(4):812–830.e14. doi:10.1016/j.immuni.2018.03.023
   PubMed Web of Science ®Google Scholar
• Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125(9):3335–3337. doi:10.1172/JCI83871
   PubMed Web of Science ®Google Scholar
• Ren L, Yi J, Yang Y, et al. Systematic pan-cancer analysis identifies APOC1 as an immunological biomarker which regulates macrophage polarization and promotes tumor metastasis. Pharmacol Res. 2022;183:106376. doi:10.1016/j.phrs.2022.106376
   Google Scholar
• Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett. 2015;368(1):7–13. doi:10.1016/j.canlet.2015.07.039
   PubMed Web of Science ®Google Scholar
• Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25(4):198–213. doi:10.1016/j.tcb.2014.11.006
   PubMed Web of Science ®Google Scholar
• Fang H, Sheng S, Chen B, et al. A Pan-Cancer analysis of the oncogenic role of cell division cycle-associated protein 4 (CDCA4) in human tumors. Front Immunol. 2022;13:826337. doi:10.3389/fimmu.2022.826337
   Google Scholar
• Borlongan MC, Saha D, Wang H. Tumor microenvironment: a niche for cancer stem cell immunotherapy. Stem Cell Rev Rep. 2024;20(1):3–24. doi:10.1007/s12015-023-10639-6
   Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–W514. doi:10.1093/nar/gkaa407
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Gruosso T, Mieulet V, Cardon M, et al. Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients. EMBO Mol Med. 2016;8(5):527–549. doi:10.15252/emmm.201505891
   Google Scholar
• Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9(2):121–132. doi:10.1016/j.ccr.2006.01.013
   PubMed Web of Science ®Google Scholar
• Clarke C, Madden SF, Doolan P, et al. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis. 2013;34(10):2300–2308. doi:10.1093/carcin/bgt208
   PubMed Web of Science ®Google Scholar
• Egelston CA, Guo W, Tan J, et al. Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor-positive breast cancer. JCI Insight. 2022;7(3). doi:10.1172/jci.insight.153963
   Google Scholar
• Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–210. doi:10.1093/nar/30.1.207
   PubMed Web of Science ®Google Scholar
• Liu J, Lichtenberg T, Hoadley KA, et al. An integrated TCGA Pan-Cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400–416.e11. doi:10.1016/j.cell.2018.02.052
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-0095
   PubMed Web of Science ®Google Scholar
• Liu C-J, F-F H, Xia M-X, Han L, Zhang Q, Guo A-Y. GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018;34(21):3771–3772. doi:10.1093/bioinformatics/bty411
   PubMed Web of Science ®Google Scholar
• Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;2017. doi:10.1200/PO.17.00073
   PubMed Web of Science ®Google Scholar
• Franz M, Rodriguez H, Lopes C, et al. GeneMANIA update 2018. Nucleic Acids Res. 2018;46(W1):W60–W64. doi:10.1093/nar/gky311
   PubMed Web of Science ®Google Scholar
• Warde-Farley D, Donaldson SL, Comes O, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(suppl_2):W214–W220. doi:10.1093/nar/gkq537
   PubMed Web of Science ®Google Scholar
• Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–W560. doi:10.1093/nar/gkz430
   PubMed Web of Science ®Google Scholar
• Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Yuan H, Yan M, Zhang G, et al. CancerSEA: a cancer single-cell state atlas. Nucleic Acids Res. 2019;47(D1):D900–D908. doi:10.1093/nar/gky939
   PubMed Web of Science ®Google Scholar
• Reinhold WC, Sunshine M, Liu H, et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 2012;72(14):3499–3511. doi:10.1158/0008-5472.CAN-12-1370
   PubMed Web of Science ®Google Scholar
• Tan K, Wang K, Zhao A, et al. Meiotic nuclear divisions 1 promotes proliferation and metastasis in hepatocellular carcinoma and is a potential diagnostic and therapeutic target gene. Med Oncol. 2022;40(1):14. doi:10.1007/s12032-022-01875-w
   Google Scholar
• Iranzo J, Martincorena I, Koonin EV. Cancer-mutation network and the number and specificity of driver mutations. Proc Natl Acad Sci USA. 2018;115(26):E6010–E6019. doi:10.1073/pnas.1803155115
   PubMed Web of Science ®Google Scholar
• Cha J-H, Chan L-C, C-W L, Hsu JL, Hung M-C. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76(3):359–370. doi:10.1016/j.molcel.2019.09.030
   PubMed Web of Science ®Google Scholar
• Izzi V, Davis MN, Naba A. Pan-Cancer analysis of the genomic alterations and mutations of the matrisome. Cancers. 2020;12(8):2046. doi:10.3390/cancers12082046
   Google Scholar
• Sahin IH, Akce M, Alese O, et al. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019;121(10):809–818. doi:10.1038/s41416-019-0599-y
   PubMed Web of Science ®Google Scholar
• van Velzen MJM, Derks S, van Grieken NCT, Haj Mohammad N, van Laarhoven HWM. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. Cancer Treat Rev. 2020;86:102024. doi:10.1016/j.ctrv.2020.102024
   PubMed Web of Science ®Google Scholar
• Capdevila-Busquets E, Badiola N, Arroyo R, Alcalde V, Soler-López M, Aloy P. Breast cancer genes PSMC3IP and EPSTI1 play a role in apoptosis regulation. PLoS One. 2015;10(1):e0115352. doi:10.1371/journal.pone.0115352
   Google Scholar
• Zhang Y, Wang D, Peng M, et al. Single-cell RNA sequencing in cancer research. J Exp Clin Cancer Res. 2021;40(1):81. doi:10.1186/s13046-021-01874-1
   PubMed Web of Science ®Google Scholar
• Hu X, Zhou S, Li H, et al. FOXA1/MND1/TKT axis regulates gastric cancer progression and oxaliplatin sensitivity via PI3K/AKT signaling pathway. Cancer Cell Int. 2023;23(1):234. doi:10.1186/s12935-023-03077-4
   Google Scholar
• Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13(7):484–492. doi:10.1038/nrg3230
   PubMed Web of Science ®Google Scholar
• Manoochehri M, Borhani N, Gerhäuser C, et al. DNA methylation biomarkers for noninvasive detection of triple-negative breast cancer using liquid biopsy. Int J Cancer. 2023;152(5):1025–1035. doi:10.1002/ijc.34337
   Google Scholar
• Yang Z, Peng M, Cheng L, et al. GT198 expression defines mutant tumor stroma in human breast cancer. Am J Pathol. 2016;186(5):1340–1350. doi:10.1016/j.ajpath.2016.01.006
   Google Scholar
• Wu R, Patel A, Tokumaru Y, et al. High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer. Breast Cancer Res Treat. 2022;193(1):49–63. doi:10.1007/s10549-022-06552-0
   Google Scholar
• Fassl A, Geng Y, Sicinski P. CDK4 and CDK6 kinases: from basic science to cancer therapy. Science. 2022;375(6577):eabc1495. doi:10.1126/science.abc1495
   PubMed Web of Science ®Google Scholar
• Gao X, Leone GW, Wang H. Cyclin D-CDK4/6 functions in cancer. Adv Cancer Res. 2020;148:147–169.
   PubMed Web of Science ®Google Scholar
• Silva Cascales H, Burdova K, Middleton A, et al. Cyclin A2 localises in the cytoplasm at the S/G2 transition to activate PLK1. Life Sci Alliance. 2021;4(3):e202000980. doi:10.26508/lsa.202000980
   Google Scholar
• Deng C-X. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 2006;34(5):1416–1426. doi:10.1093/nar/gkl010
   PubMed Web of Science ®Google Scholar
• Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95(11):866–871. doi:10.1111/j.1349-7006.2004.tb02195.x
   PubMed Web of Science ®Google Scholar
• Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002–1014. doi:10.1016/S0140-6736(21)01206-X
   PubMed Web of Science ®Google Scholar
• Xu H, Van der Jeught K, Zhou Z, et al. Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. J Clin Invest. 2021;131(10). doi:10.1172/JCI146832
   Web of Science ®Google Scholar
• Zhou X, Yao Z, Bai H, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021;22(9):1265–1274. doi:10.1016/S1470-2045(21)00333-8
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034. doi:10.1084/jem.192.7.1027
   PubMed Web of Science ®Google Scholar
• Mittal S, Brown NJ, Holen I. The breast tumor microenvironment: role in cancer development, progression and response to therapy. Expert Rev Mol Diagn. 2018;18(3):227–243. doi:10.1080/14737159.2018.1439382
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T cells and human disease. Annu Rev Immunol. 2020;38(1):541–566. doi:10.1146/annurev-immunol-042718-041717
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3(11):1427–1438. doi:10.1158/1535-7163.1427.3.11
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. doi:10.1186/bcr2419
   PubMed Web of Science ®Google Scholar
• Bollard J, Miguela V, Ruiz de Galarreta M, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2017;66(7):1286–1296. doi:10.1136/gutjnl-2016-312268
   PubMed Web of Science ®Google Scholar
• Helal M. Prenatal effects of transplacental exposure to ifosfamide in rats. Biotech Histochem. 2016;91(5):357–368. doi:10.1080/10520295.2016.1176253
   PubMed Web of Science ®Google Scholar
• Lonetti A, Cappellini A, Bertaina A, et al. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. J Hematol Oncol. 2016;9(1):114. doi:10.1186/s13045-016-0344-4
   PubMedGoogle Scholar
• Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS. mTOR mediated anti-cancer drug discovery. Drug Discov Today Ther Strateg. 2009;6(2):47–55. doi:10.1016/j.ddstr.2009.12.001
   PubMedGoogle Scholar
• Wei L, Chintala S, Ciamporcero E, et al. Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. Oncotarget. 2016;7(47):76374–76389. doi:10.18632/oncotarget.13062
   Google Scholar
• Knight SD, Adams ND, Burgess JL, et al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med Chem Lett. 2010;1(1):39–43. doi:10.1021/ml900028r
   PubMed Web of Science ®Google Scholar